Form 4: Biohaven Director Antonijevic Acquires Stock Options

Director Irina Antonijevic acquired 31,716 stock options in Biohaven Ltd. on May 5, 2025, according to a Form 4 filing.

Summary

• Irina Antonijevic, a director of Biohaven Ltd., acquired 31,716 stock options on May 5, 2025.
• The exercise price of these options is $22.62.
• The options vest on the earlier of May 5, 2026, or the date of the 2026 Annual Meeting of Shareholders, contingent upon continuous service with the issuer.
• The options expire on May 5, 2035.
• Following the transaction, Antonijevic directly owns 31,716 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly standard.
• The number of options granted is within the typical range for director compensation at companies of Biohaven's size and stage.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates

Keywords

stock options, Biohaven, director, Antonijevic, Form 4, acquisition, vesting